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Background:  Challenges  commonly  encountered  in  HTA of  orphan  medicinal  products
(OMPs)  were  identiﬁed  in  Advance-HTA.  Since  then,  new  initiatives  have  been  developed
to  speciﬁcally  address  issues  related  to HTA  of OMPs.
Objective  and  methods:  This  study  aimed  to understand  why  these new  HTA  initiatives
in  England,  Scotland  and at European-level  were  established  and  whether  they  resolve
the challenges  of OMPs.  The  work  of  Advance-HTA  was updated  with  a  literature  review
and  a conceptual  framework  of  clinical,  regulatory  and  economic  challenges  for OMPs  was
developed.  The  new  HTA programmes  were  critiqued  against  the  conceptual  framework
and  outstanding  challenges  identiﬁed.
Results:  The  new  programmes  in England  and  Scotland  recognise  the  challenges  identiﬁed  in
demonstrating  the value  of  ultra-OMPs  (and OMPs)  and  that  they  require  a different  process
to standard  HTA  approaches.  Wider  considerations  of  disease  and  treatment  experiences
from  a multi-stakeholder  standpoint  are  needed,  combined  with  other  measures  to deal
with  uncertainty  (e.g.  managed  entry  agreements).  While  approaches  to assessing  this  new
view  of  value  of OMPs,  extending  beyond  cost/QALY  frameworks,  differ,  their  criteria  are
similar. These  are  complemented  by  a European  initiative  that  fosters  multi-stakeholderPlease cite this article in press as: Nicod E, et al. HT
ing with orphan medicinal products: Process evaluation in
http://dx.doi.org/10.1016/j.healthpol.2017.03.009
dialogue  and  consensus  about  value  determinants  throughout  the  life-cycle  of  an  OMP.
Conclusion:  New  HTA  programmes  speciﬁc  to OMPs  have  been  developed  but  questions
remain  about  whether  they  sufﬁciently  capture  value  and manage  uncertainty  in clinical
practice.
© 2017  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
the  CC  BY-NC-N
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1. Introduction
At local and national levels, Health Technology Assess-
ment (HTA) is increasingly being used to inform drug
coverage decisions to ensure that rational, evidence-based
choices are made within a limited budget [1]. OMPs gener-
ally undergo the same HTA processes as drugs for more
prevalent diseases [2,3], even if an orphan designation
distinction is previously made at regulatory level. Is this
approach fair, or should different approaches be used?
Rare diseases affect small patient numbers (with a
prevalence of less than ﬁve in 10,000 in Europe), and
are life-threatening, debilitating and frequently genetically
acquired [4]. An estimated number of 5000 to 8000 rare
diseases exist, affecting 6–8% of the population in Europe.
Based on the principle of equity [5], where “patients suf-
fering from rare conditions should be entitled to the same
quality of treatment as other patients” [6], incentives were
implemented in medicines regulation processes in the EU
and other countries to stimulate research and development
for rare disease treatments [7]. Medicinal products treating
a rare disease are eligible to receive an orphan designa-
tion by regulators. Upon receiving this designation, they
are referred to as Orphan Medicinal Products (OMPs), and
beneﬁt from incentives that allow expedited authorisation
with more limited evidence than other medicinal products.
However, this does not give patients automatic access to
the treatments, as their reimbursement often depends on
HTA.
A Work Package in the Advance-HTA project systemat-
ically investigated HTA decision processes for a sample of
ten OMPs between October 2007 and December 2012 in
four European countries (England, Scotland, Sweden and
France). It identiﬁed a number of issues that HTA bodies
faced when making these difﬁcult coverage decisions [8].
Although these issues are also encountered for drugs treat-
ing more prevalent diseases, they are more challenging
for OMPs [9]. When economic evaluation is used in HTA,
OMPs often fail to meet standard cost-effectiveness crite-
ria due to their high acquisition costs and the uncertain
evidence-based produced, and so would generally not be
recommended for coverage [5,10–12]. Despite the com-
mon  problems with OMPs, there were different approaches
to dealing with them in the four countries, with different
issues raised as most important and different judgments
about the acceptable levels of uncertainty. This included,
for example, accepting greater uncertainty when consid-
ering the orphan status or conditional licensing of the
medicine, imposing future reassessments, or improving the
incremental cost-effectiveness ratio (ICER) with a patient
access scheme [8]. This raised the question as to whether
we [society] are willing to pay more for rare disease
patients [13]. A number of surveys aiming to elucidate this
question found little support when resources are taken
from more prevalent diseases, but a positive response if
it is for more serious conditions with no treatment alterna-
tives [10,11,14–17]. This emphasizes the recognized needPlease cite this article in press as: Nicod E, et al. HT
ing with orphan medicinal products: Process evaluation i
http://dx.doi.org/10.1016/j.healthpol.2017.03.009
for more suitable approaches to appraising orphan drugs,
particularly with regards to the challenges encountered
during the assessments. PRESS
 xxx (2017) xxx–xxx
Since the Advance-HTA project, new HTA programmes
speciﬁc for OMPs or ultra-OMPs (treating less than one in
50,000) have recently been developed and/or implemented
within Europe (e.g. the Patient and Clinician Engage-
ment (PACE) meeting and ultra-OMP decision-making
programmes at the Scottish Medicines Consortium (SMC);
the Highly Specialised Technology (HST) programme at the
National Institute for Health and Care Excellence (NICE) in
England; or the Mechanism of Coordinated Access (MoCA)
to OMPs, a European initiative initiated during the Belgian
EU Presidency [18]). This research updated the literature
search undertaken for the Advance-HTA project to identify
challenges in assessing OMPs. It then developed a con-
ceptual framework to explain these issues. The rationale
for new HTA programmes for OMPs was then reviewed
and compared with the HTA-level issues identiﬁed in the
framework. The outputs of the new programmes were
explored to examine their impact.
2. Materials and methods
Previous ﬁndings from the Advance-HTA project were
used to summarise the types of challenges faced when deal-
ing with OMPs in four countries [8,19]. This was  based on a
document analysis of HTA reports issued by four HTA  bod-
ies in four countries (NICE in England, SMC  in Scotland, the
Dental and Pharmaceutical Beneﬁts Board (TLV) in Sweden,
and the Haute Autorité de Santé (HAS) in France). This sum-
mary was  generated by the lead author, and received two
rounds of comments by non-institutional co-authors (KF,
LA), to ensure their clarity and completeness. A review
of the literature was  conducted to understand how issues
relating to the assessment of treatments for rare diseases
are reﬂected at HTA-level. The databases Web  of Science
and Medline were searched using the following MeSH
heading: (“orphan drug” OR “rare disease” OR “rare con-
dition” OR “rare disorder”) AND (“uncertainty” OR “health
technology assessment”). The abstracts were reviewed and
selected if they referred to issues encountered with OMPs
at HTA-level or to the type of uncertainty encountered with
OMPs. We  also cross-checked the references included in the
papers identiﬁed of interest, and searched the grey litera-
ture, including websites from key institutions or initiatives
in the rare disease ﬁeld (e.g. Eurordis, European Commis-
sion). On this basis, a conceptual framework was built
summarising the challenges that arise due to the nature of
OMPs in terms of drug development and their implications
for HTA (Fig. 1).
Representatives leading new HTA programmes for
OMPs and/or ultra-OMPs were invited to participate in
this research. These included the HST programme at NICE,
the PACE programme and ultra-OMP decision-making pro-
gramme  at SMC, and the MoCA project. SMC  is the HTA body
in Scotland that undertakes HTA for all medicinal products.
Within this remit, new processes have been created for cer-
tain types of medicines (e.g. OMPs and ultra-OMPs), these
have been referred to as “programmes” in this paper. AA programme response to the challenges of deal-
n selected European countries. Health Policy (2017),
questionnaire developed by some of the authors (EN, KF,
LA) was sent by email to these representatives. It included
open-ended questions about: (a) their deﬁnition of an
OMP and ultra-OMP; (b) the reasons for establishing these
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Fig. 1. Conceptual framework of OMP  development and assessment challenges.
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. Results
.1. Issues with OMPs
OMPs often exceed cost-effectiveness thresholds in
TA due to lack of evidence about clinical beneﬁtPlease cite this article in press as: Nicod E, et al. HT
ing with orphan medicinal products: Process evaluation in
http://dx.doi.org/10.1016/j.healthpol.2017.03.009
nd high acquisition costs. Moreover, evidence on their
ost-effectiveness is typically characterised by greater
ncertainty. This can lead to rejection through the rou-
ine approval process, or funding restricted to subgroupsmmonly encountered for OMPs, how they relate to the nature of OMPs
of patients where their use is considered most effective or
cost-effective [5,11,20–23].
These challenges emerge from the clinical, regulatory
and economic obstacles encountered throughout the OMP
development process (Fig. 1). Clinical challenges relate
to the scarce scientiﬁc literature and number of clinical
experts available [24], where often little is known about the
diseases’ epidemiology, natural history or best treatment
pathways [25,26]. This affects the ability to run conﬁrma-
tory trials in terms of design, e.g. lack of agreement on
relevant endpoints [22], treatment pathways or appropri-
ate trial durations [22], lack of active comparator [27], lack
of validated patient reported outcome instruments [28]
and conduct (e.g. recruitment [25], diagnosis [24], mul-
tiple clinical trial sites due to the few patient numbers
[24]). The small patient numbers and relatively short dura-
tion of these clinical trials often imply that intermediate
outcomes such as biomarkers or the six-minute walk test
are studied rather than longer-term clinical outcomes [22].
These, in addition to the regulatory incentives for expeditedA programme response to the challenges of deal-
 selected European countries. Health Policy (2017),
approval based on phase II trials, may  result in lower qual-
ity evidence generation for OMPs [29,30]. The statistical
power to detect clinically meaningful outcomes from these
often small-scale trials is limited [31]. Given the severity,
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chronicity, life-threatening and disabling nature of these
rarer diseases, the economic, psychological, and quality of
life burden is also frequently high for patients, their families
and carers, the healthcare system and society [25,27,32].
These challenges were reﬂected in the types of issues
highlighted by the HTA bodies across the OMPs previously
analysed in the Advance-HTA project (Fig. 1, eAppendix
A) [8]. Misalignments with marketing authorisation incen-
tives were seen, where some of the assessments relied
on phase II trials following early marketing authorisa-
tion under exceptional circumstances or with conditional
approval [8]. Other issues relating to the nature of these
rare diseases included those around sample size and sta-
tistical power, clinical pathways, comparators, clinical,
health-related quality of life or patient reported out-
comes endpoints, trial duration, or subgroup data. The base
case ICER estimates of NICE and SMC’s assessment were
generally high (> £30,000/QALY in 60–70% of cases) and
sensitivity analyses showed high levels of uncertainty. This
was a consequence of high acquisition costs, marginal ben-
eﬁts and uncertain evidence (Fig. 1, sAppendix A) [8]. These
are in line with the issues seen for OMPs highlighted by
Menon and colleagues [9].
3.2. New programmes for OMPs and ultra-OMPs
3.2.1. Rationales
It was generally recognized that OMPs do not usu-
ally prove to be cost-effective based on conventional HTA
methods designed for common diseases. Over several years
HTA bodies have been criticized about their evaluation pro-
cesses for OMPs and ultra-OMPs [33,34], where there may
have been more leniency when dealing with them. As a
result, HTA bodies have been facing political pressures to
change their processes and be more transparent. At the
same time, research has been conducted to identify the
types of issues HTA bodies faced for OMPs within these con-
ventional processes. The aim of this paper was to compare
how the new programmes being implemented are tackling
the ﬁndings from this research.
In England, NICE has been responsible for assessing
selected ultra-OMPs since 2013 and established the new
HST programme to do this [35]. HST’s remit is to evaluate
the beneﬁts and costs of a technology within its market-
ing authorization for the treatment of a speciﬁc disease
for national commissioning by NHS England using a spe-
ciﬁc decision-making framework. About three ultra-OMPs
undergo the HST process each year. The products are cho-
sen in the same manner as other technologies through
a topic prioritization process led by the Department of
Health. Ultra-OMPs not selected for the HST programme
undergo the usual commissioning process via NHS England.
OMPs can undergo the same process as non-OMPs at NICE
(e.g. single or multiple technology appraisal process) or be
part of the commissioning process at NHS England. The
Department of Health mandates NICE to issue a coverage
decision, which should be enacted within 90 days.Please cite this article in press as: Nicod E, et al. HT
ing with orphan medicinal products: Process evaluation i
http://dx.doi.org/10.1016/j.healthpol.2017.03.009
In Scotland, SMC  assesses all new medicinal products
and new indications for existing products. Manufacturers
make evidence submissions and SMC  recommends routine,
restricted, or not recommended use in NHS Scotland. If a PRESS
 xxx (2017) xxx–xxx
manufacturer does not make a submission for a product,
then it is not recommended for routine use. In 2013, three
petitions were brought to the attention of the Scottish Par-
liament Health and Sport Committee about lack of access to
ultra-OMPs due to not recommended advice from SMC. The
Committee report to the Scottish Government prompted a
major review of processes with all stakeholders, and led
SMC to develop new, more ﬂexible programmes for OMPs
and ultra-OMPs (and end-of-life treatments) in order to
increase patient access. These new approaches include the
PACE meeting and the new decision-making framework for
ultra-OMPs [36].
At European-level, the challenges and discrepancies
in access to OMPs across Member States triggered the
implementation of the MoCA project [37]. The MoCA pro-
vides a mechanism for European countries to collaborate
on access for patients with rare diseases to OMPs via a
voluntary, dialogue-based approach, with ﬂexible interac-
tions between key stakeholders to agree on the value of
OMPs [38]. This approach aims to facilitate a quicker and
broader access to OMPs, to allow for greater equity in access
to OMPs across Member States, and to better coordinate
the collection of patient-reported outcomes and real-life
experiences. Payers should beneﬁt from a better documen-
tation of the treatment’s added value, more precise budget
estimates and efﬁcient price negotiations, while manufac-
turers gain a better predictability, rapid uptake of their
products, and understanding of payers’ expectations. Par-
ticipation is initiated upon the manufacturer’s expression
of interest. MoCA is currently being piloted, and focuses
on the early dialogue phase about evidence generation and
how to provide access to these OMPs.
3.2.2. New processes
The HST evaluation process is similar to NICE’s con-
ventional technology appraisal processes, with the main
difference being the criteria accounted for deﬁned by HST’s
value framework [39]. When evaluating costs, the com-
mittee also considers the cost to the NHS and personal
social services. It takes into account the total budget for
specialised services and its allocation, as well as the scale
of investment in comparable areas of medicine. The com-
mittee assesses what could be considered a reasonable
cost for the medicine in the context of recouping manu-
facturing, research and development costs from sales to a
limited number of patients. Interim methods for the HST
programme are currently under review.
In SMC’s process, the New Drugs Committee drafts the
HTA advice according to the standard clinical and cost-
effectiveness framework. The manufacturer may  request
that SMC  convenes a PACE meeting if the draft advice issued
is to not recommend the use of the medicine [40]. Patients,
clinicians and the pharmaceutical company then submit a
written report to the PACE meeting, with patient and clini-
cian representatives contributing to further discussions in
person, leading to a joint PACE statement that is circulated
in full to the SMC  members, summarized in the DetailedA programme response to the challenges of deal-
n selected European countries. Health Policy (2017),
Advice Document and highlighted in a verbal report by the
PACE Chair during the SMC  meeting. Additionally for OMPs,
SMC  will account for additional criteria deﬁned in their
framework of explicit decision-making criteria for ultra-
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MPs [36]. This adds about one to three months to the
tandard 18-week SMC  process. At this point in the process,
he company also has the option to offer a new or revised
atient Access Scheme (conﬁdential discount) to improve
alue for money.
By contrast, the MoCA is not a standard HTA programme
ut a collaborative process that involves a sustained dia-
ogue between the OMP  developer, a group of payers
nd other stakeholders from various European countries
37]. Participants consist of companies with new prod-
cts, EURORDIS, an umbrella patient organization, which
lso ensures the participation of relevant patient groups,
nd volunteers from the Medicine Evaluation Committee
MEDEV). The main difference with the parallel scientiﬁc
dvice at the European Medicines Agency (EMA) is that
articipation from the stakeholders is voluntary and not
nitiated by the applicant, allowing for participation in the
ialogue of smaller countries. It also differs from the early
ialogue with HTA bodies in that it focuses on practical,
ragmatic, legal and economic aspects of reimbursement
ecision-making, and integrates the HTA-relevant ques-
ions into this context.
.2.3. Appraisal criteria
HST’s decision-making criteria include considerations
round the nature of the condition, impact of the new
echnology, including its impact beyond direct health ben-
ﬁts and on the delivery of specialised services, costs to
he NHS and Personal Social Services, and value for money
39]. For each criterion, a sub list of criteria is provided
Table 1). The methods guidelines give freedom in the form
f the health economic evaluation that can be used, e.g.
ost-consequence, cost-utility. To date, all companies have
hosen to submit a cost-utility analysis.
The SMC  ﬁrst considers the traditional HTA measures,
.g. ICER, while PACE assesses where these did not cap-
ure certain aspects of the disease or conditions by giving
atients and clinicians the opportunity to comment on
heir experiences. This includes clinical, psychological and
ocial issues, such as the added value of the medicine
or the patients, their families and carers. Participants are
sked to focus on quality of life issues, which could be
mproved by taking the medicine such as the ability to
ontinue work or education, treatment convenience, abil-
ty to improve symptom management (e.g. pain, extreme
iredness), relieve psychological distress, enable self-care
r maintain independence and dignity. In addition to a
ACE meeting, the assessment of an ultra-OMP is based on
 dedicated framework of explicit decision-making criteria,
hich include the same criteria as for the HST programme,
etting out the higher level criteria only (Table 1) [36]. A
ost-utility analysis is requested as part of the company
ubmission to assess value for money. Other forms of eco-
omic evaluations, including cost-consequence analysis,
re accepted if the submitting company believes an evalu-
tion using QALYs is not feasible.
By contrast, the MoCA aims to facilitate a dialoguePlease cite this article in press as: Nicod E, et al. HT
ing with orphan medicinal products: Process evaluation in
http://dx.doi.org/10.1016/j.healthpol.2017.03.009
mongst key stakeholders throughout the OMP’s develop-
ent life cycle. Dialogue may  start at any point during the
ifecycle of an OMP  and results in a ﬁnal report containing
earnings and recommendations, which is conﬁdential and PRESS
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non-binding, unless otherwise agreed. Companies as well
as payers are free to opt out at any time (until a contract is
signed) and the process is currently free of charge.
3.3. Dealing with uncertainty commonly encountered
with OMPs
All programmes agreed that the challenges highlighted
in Fig. 1 (eAppendix A) are in line with those commonly
encountered for both OMP  and ultra-OMPs. The com-
mon  characteristic of NICE and SMC’s programmes is to
account for a broader range of criteria and include patient
and clinician input to help address uncertainty and better
understand the value of a product. The decision then relies
on the Committee’s judgment as to whether this evidence
is sufﬁcient to overcome greater uncertainty. This may  be
combined with other measures helping deal with uncer-
tainty such as the ability to implement a Managed Access
Agreement (MAA) (which is a type of outcomes based man-
aged entry agreement) at HST, or Patient Access Schemes
(PAS) (e.g. simple discounts) at HST and SMC  (Table 2).
A MAA  scheme facilitates access to ultra-OMPs, whilst
generating valuable evidence in collecting ‘real-world’
data. All stakeholders agree on a set of criteria and con-
ditions that need to be fulﬁlled by patients, clinicians and
industry. These include conditions and criteria for patient
eligibility, start and stop criteria, data collection and mon-
itoring (e.g. implementation of registries, data collected
and assessments to be made), appeal process, ownership
of data, or exit strategy [41]. There may  be some additional
ﬁnancial arrangements between payers and the relevant
pharmaceutical company. At the end of the MAA  period,
the product is re-evaluated via the HST process. If no ben-
eﬁt is gained, the ultra-OMP will no longer be available to
any patient via the NHS. These drugs are usually dispensed
within specialised services, which allows for patients to
receive expert care and infrastructure to manage patients
with the condition in question.
MoCA aims to address these issues in advance through
the conversations among stakeholders about how to best
generate evidence for HTA and payers with reasonable
resources, deﬁning patient-relevant outcomes, demon-
strating cost-effectiveness, and designing pathways for
equitable and sustainable ﬁnancing. This involves discus-
sions about the design and implementation of registries,
the feasibility of managed entry agreements, and deliv-
ery pathways (e.g. how to establish or designate treatment
centers for very rare diseases with cross-border access,
where it is not feasible to establish one or more centers per
Member State − a particularly relevant issue for advanced
therapy medicinal products).
3.4. Challenges encountered with these new programmes
The HST programme is challenged by the number of new
products needing an evaluation and its capacity to under-
take only three evaluations per year. Other challengesA programme response to the challenges of deal-
 selected European countries. Health Policy (2017),
include the ability to assess and manage the uncertainty
in the evidence submitted. With limited natural history
data, short and small-scale trials, careful consideration of
the evidence in line with the company value proposition
ARTICLE IN PRESSG ModelHEAP-3714; No. of Pages 12
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Table 1
Assessment criteria accounted for during the HST and PACE processes.
Criterion to assess ultra-OMPs NICE HST Value
Framework
SMC  ultra-OMP
Framework
SMC  PACE
group(non-
exhaustive)
Nature of the condition
√ √
Patient clinical disability with current standard care
√
Impact of the disease on family/carers’ quality of life
√
Extent and nature of current treatment options
√
Unmet need
√
Severity of the condition
√
Impact of the new technology
√ √ √
Clinical effectiveness
√
Overall magnitude of health beneﬁts to patients, and where relevant, their
families/carers
√ √
Heterogeneity of health beneﬁts within the population
√
Robustness of the current evidence base and anticipated contribution the
guidance may  make to strengthen in
√
Treatment continuation rules (if applicable)
√
Cost to the NHS and Personal Social Services (PSS)
√ √
Budget impact of technology in the NHS and PSS
√
Robustness of costing and budget impact information
√
Patient access schemes
√
Value for money
√ √
Incremental beneﬁt of the new technology compared with current treatment
options (technical efﬁciency)
√
Nature and extent of other resources needed to enable the technology to be
used (productive efﬁciency)
√
Impact of the new technology on the budget available for specialised
commissioning (allocative efﬁciency)
√
Opportunity cost of the technology (effect of investing in this technology
rather than in another specialised service)
√
Impact of the technology beyond direct health beneﬁts
√ √
Signiﬁcant beneﬁts other than health
√
Whether a substantial proportion of the costs (savings) or beneﬁts are
incurred outside of the NHS and PSS
√
Potential for long-term beneﬁts to the NHS and society of research and
innovation
√
Impact of the technology on the delivery of the specialised service
√ √
Stafﬁng and infrastructure requirements
√
Training requirements and need to plan for expertise
√
Best clinical practice in delivering the service
√
Service/infrastructure changes/beneﬁts as a result of using the medicine
√
Impact of the new technology on quality of life
√
The ability to continue to work or education
√
The management of symptoms such as pain and extreme tiredness
√
Helping relieve psychological distress
√
Convenience of how and where the treatment is received
√
The ability to self-care or maintain independence and dignity
√
Time for accompanied visits for treatment
√
Requirement for assisting the patient with personal care and support
√
Out of pocket expenses
√
Impact on family life
√
Impact on the carer’s ability to go to work
√
Clinical issues
Speciﬁc patient groups that may  beneﬁt more from use of the medicine
√
Place in the patient pathway
√
√
cottish 
: PatienLegend: NICE: National Institute for Health and Care Excellence; SMC: S
HAS:  Haute Autorité de Santé; HST: Highly Specialised Technology; PACE
is needed. New approaches are also needed to allow better
management of the risk burden relating to the uncertain
evidence that the NHS is willing to bear.
The SMC  ultra-OMP framework allows companies to
make a submission that emphasizes the wider beneﬁts ofPlease cite this article in press as: Nicod E, et al. HT
ing with orphan medicinal products: Process evaluation i
http://dx.doi.org/10.1016/j.healthpol.2017.03.009
medicines that may  not be easily captured in the QALY.
Although the Committee now has more ﬂexibility to accept
medicines with a higher ICER than would convention-
ally have been accepted, the extremely high acquisitionMedicines Consortium; TLV: Dental and Pharmaceutical Beneﬁts Board;
t and Clinician Engagement; OMP: Orphan Medicial Product.
costs of many of these medicines, coupled with very sig-
niﬁcant uncertainty about the magnitude and duration of
clinical beneﬁts, means that the most plausible ICER may
be £500,000 or more, which is well above the perceived
willingness-to-pay threshold (Table 2).A programme response to the challenges of deal-
n selected European countries. Health Policy (2017),
The MoCA project’s main challenge is that there is no
single payer voice. Each country has different health care
systems, laws, economies, and priorities. It is not always
possible to ﬁnd “one-size-ﬁts-all” solutions − ultimately,
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Table 2
Products assessed by SMC  ultra-orphan process and informed by PACE (May 2014–September 2016).
Medicine Indication Recommendation Economic evaluation* SMC  modiﬁers for ultra-OMPs
Indications other than cancer
Ataluren Duchenne muscular dystrophy Not recommended £793,498/QALY versus BSC (Public ICER, ICER
including PAS conﬁdential).
− absence of other treatments of proven
beneﬁt.
Eculizumab Paroxysmal nocturnal haemoglobinuria Not recommended Cost-consequence analysis: estimated
incremental QALY gain of 11.96 with
eculizumab compared to BSC and a life year
gain of 9.23 (lifetime incremental costs
remained in conﬁdence).
− substantial improvement in quality of life,
−  absence of other treatments of proven
beneﬁt.
Eculizumab Atypical haemolytic uraemic syndrome Not recommended Cost-consequence analysis: Estimated lifetime
QALY gain of 15.3 with eculizumab compared
to BSC and a life year gain of 14 (lifetime
incremental costs remained in conﬁdence).
− substantial improvement in quality of life,
−  potential to bridge to a deﬁnitive therapy,
−  absence of other treatments of proven
beneﬁt.
Elosufase  alfa Mucopolysaccharidosis type IVa Not recommended £829,870/QALY versus standard medical care,
including a PAS (simple discount) and a 3.5%
discount rate applied to costs and beneﬁts.
£822,265/QALY using a societal perspective.
− absence of other treatments of proven
beneﬁt.
Ivacaftor  Cystic ﬁbrosis with certain genetic mutations Not recommended Early ivacaftor versus:
− late ivacaftor: £484,386/QALY
− standard of care: £609,316/QALY
(Public ICER, ICER including PAS conﬁdential).
− absence of other treatments of proven
beneﬁt.
Pasireotide Acromegaly where surgery is not an option
and are inadequately controlled on other
treatments
Accepted £5855/QALY versus monthly somatostatin
analogues.
− potential to bridge to a deﬁnitive therapy.
Cancer  indications
Bevacizumab (in combination) Persistent, recurrent or metastatic cervical
cancer
Accepted £43,624/QALY for
bevacizumab + cisplatin + paclitaxel versus
carboplatin + paclitaxel, including a PAS
(conﬁdential discount as a rebate on the list
price of bevacizumab).
− substantial improvement in life expectancy.
Bevacizumab (in combination) Platinum resistant, recurrent epithelial
ovarian, fallopian tube or primary peritoneal
cancer
Restricted £50,538/QALY versus chemotherapy alone. − absence of other treatments of proven
beneﬁt.
Blinatumomab Philadelphia chromosome negative relapsed or
refractory B-precursor acute lymphoblastic
leukaemia
Accepted £52,201/QALY versus standard care
(multi-drug chemotherapy), including a PAS.
− absence of other treatments of proven
beneﬁt,
−  potential to bridge to a deﬁnitive therapy.
Bosutinib Previously treatment Philadelphia
chromosome positive chronic myelogenous
leukaemia
Accepted £39,119-£62,619/QALY depending on the
model and disease phase (Public ICER, ICER
including PAS (simple discount) conﬁdential).
− substantial improvement in quality of life,
−  absence of other treatments of proven
beneﬁt.
(resubmission)
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Table 2 (Continued)
Medicine Indication Recommendation Economic evaluation* SMC  modiﬁers for ultra-OMPs
Brentuximab vedotin Relapsed or refractory CD30+ Hodgkin
lymphoma
Restricted £43,731/QALY in both subgroups considered. − substantial improvement in life expectancy,
− substantial improvement in quality of life,
−  the potential to bridge to a deﬁnitive
therapy,
−  absence of other treatments of proven
beneﬁt.
Cabozantinib Progressive, unresectable locally advanced or
metatstatic medullary thyroid cancer
Not recommended £93,141/QALY versus BSC. − absence of other treatments of proven
beneﬁt.
Ceritinib  Previously treated anaplastic lymphoma
kinase positive advance non-small lung cancer
Accepted £50,908/QALY versus BSC, including a PAS
(simple discount).
− substantial improvement in life expectancy.
Crizotinib First-line treatment of adults with anaplastic
lymphoma kinase (ALK)-positive advanced
non-small cell lung cancer
Accepted £48,355/QALY versus pemetrexed plus
cisplatin or carboplatin, including a PAS
(simple discount).
− substantial improvement in quality of life.
Ibrutinib Relapsed or refractory mantle cell lymphoma Accepted £41,798/QALY versus physician’s choice of
treatment, including a PAS (discount)
Idelalisib Refractory follicular lymphoma Accepted £62,653/QALY versus standard care (Public
ICER, ICER including PAS conﬁdential).
Lenvatinib Adult patients with progressive, locally
advanced or metastatic, differentiated
(papillary/follicular/Hürthle cell) thyroid
carcinoma, refractory to radioactive iodine
Accepted £49,525/QALY versus sorafenib, including a
PAS (simple discount).
Olaparib Maintenance treatment of platinum sensitive
relapsed BCRA mutated high grade serous
epithelial ovarian, fallopian tube or primary
peritoneal cancer
Not recommended £49,236/QALY versus watch and wait,
including a PAS.
− absence of other treatments of proven
beneﬁt.
Regorafenib Unresectable or metastatic gastrointestinal
stroma tumours
Accepted £31,200/QALY versus BSC, including a PAS
(conﬁdential discount).
− substantial improvement in quality of life,
−  absence of other treatments of proven
beneﬁt.
Trametinib In combination with dabrafenib for the
treatment of adult patients with unresectable
or metastatic melanoma with a BRAF V600
mutation
Restricted £35,134/QALY versus dabrafenib, including a
PAS (discount); and £39, 956/QALY versus
vemurafenib, including a PAS (discount)
− substantial improvement in life expectancy,
− substantial improvement in quality of life.
Trastuzumab (in combination) HER2 positive metastatic adenocarcinoma of
the stomach or gastro-oesophageal junction
Restricted £41,347/QALY versus epirubicin, oxaliplatin
and capecitabine.
− substantial improvement in life expectancy,
− absence of other treatments of proven
beneﬁt.
(2nd  resubmission)
*ICER as used for decision-making unless conﬁdential PAS applied. Sensitivity analyses were performed, and various ICERs presented, but this is the ICER that appears to have been accounted for in the decision.
Legend:  SMC: Scottish Medicines Consortium; QALY: Quality-adjusted Life Years; PAS: Patient Access Scheme; ICER: Incremental Cost-effectiveness Ratio; BSC: Best Supportive Care
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ach national authority will have to make a decision, but
his may  be expedited through the previous discussions.
here are also challenges in designing appropriate reg-
stries, which can accommodate the needs of regulators,
TA bodies and payers, and are workable across borders.
oreover, at many payer institutions resources for this
ype of activity are scarce.
.5. Impact of new programmes
To date, three ultra-OMPs have undergone the HST pro-
ess and were approved, three are in the process. Two  of the
hree were approved under an MAA. For example, elosul-
ase alfa in the treatment of mucopolysaccharidosis type
Va in adults and children was approved under the con-
ition of a MAA  achieved through a working partnership
etween NHS England, NICE, a patient organization, the
anufacturer and a clinical expert. The MAA  was designed
o assess patient response to treatment based on pre-
eﬁned criteria monitoring clinical data and quality of life.
he outcomes covered include a combination of registry
ata and condition-speciﬁc outcome measures. The MAA
lso included conﬁdential negotiated commercial terms
nd a stopping clause for those patients not meeting treat-
ent targets [41].
Since the introduction of the PACE programme (May
014-September 2016), the acceptance rate for eligi-
le medicines has increased by 58% compared to the
011–2013 period, from 48% to 76%, and the number
f non-submissions has reduced by around a third. The
ACE programme has proven helpful to facilitate joint dia-
ogue between patient groups, clinicians and HTA staff
o highlight the impact of a condition on patients and
heir personal experience together with the expected wider
eneﬁts and disadvantages of a new medicine. The PACE
tatement is expected to be a signiﬁcant factor in the SMC
ecision. For example, the output of the PACE meeting
ssessing ruxolitinib in the treatment of disease-related
plenomegaly in adults clearly illustrated the symptom
urden in primary myeloﬁbrosis and its devastating effect
n the quality of life for patients and their families. The
eneﬁts from treatment response were also highlighted in
erms of the ability to return to a virtually normal life and
n some cases to work, the improvement of family rela-
ionships following a reduced dependency on carers, the
asing of the psychological burden on patients, and their
bility to regain their personal dignity and independence.
atients were also less likely to need inpatient or outpa-
ient care. The utility values for treatment were derived
sing a relatively new condition-speciﬁc HRQol measure,
he MF-8D. The novelty of this measure, together with
he relatively high utility values from responding patients,
as one of several key uncertainties in the economic case.
he knowledge of the patient experience derived from
he PACE process provided some reassurance to decision-
akers in this context. At this stage, a Patient Access
cheme improving the cost-effectiveness of the medicinePlease cite this article in press as: Nicod E, et al. HT
ing with orphan medicinal products: Process evaluation in
http://dx.doi.org/10.1016/j.healthpol.2017.03.009
as also submitted by the company. For elosulfase alfa,
reviously discussed within the HST context, a number
f considerations about the condition’s severity and treat-
ent beneﬁt were also accounted for during the PACE PRESS
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meeting and within the ultra-OMP decision-framework.
These were not sufﬁcient, and a negative recommendation
was issued because of weaknesses in the economic case
and the high ICER (>£800,000/QALY), where the medicine
was unlikely to provide value for money.
To date, no product discussions within the MoCA frame-
work have advanced to the point of speciﬁc agreements
on managed entry. Companies participating in the discus-
sions have termed them as very useful to gain insights into
the problems payers face, and into the outcomes that mat-
ter to patients and payers. This is especially important for
smaller and newer companies, which are those most likely
to ﬁnd the MoCA process useful [42]. Payers get an earlier
opportunity to plan for introducing the new therapies and
developing new models for access.
4. Discussion
While the challenges in dealing with orphan drugs are
generally recognized, the approaches to tackle these var-
ied. Differences were seen in the technologies selected to
undergo these new progammes. The same ultra-OMPs do
not necessarily undergo NICE’s HST and SMC’s ultra-OMPs
evaluation programmes despite their common deﬁnition.
Those not selected by the Department of Health for NICE’s
HST programme proceed through the usual commissioning
process, where NHS England makes their own decision on
how to provide access. OMPs undergo conventional HTA
processes at NICE and SMC. In the latter case, additional
considerations are accounted for via the PACE programme
for those drugs that were not recommended during the
initial standard HTA assessment by the New Drugs Com-
mittee.
The main commonality across these new programmes
at NICE and SMC  is the recognition that the QALY may not
capture all elements of value and that wider considerations
are needed from a multi-stakeholder standpoint. These
considerations are accounted for during the deliberative
process and contribute to accepting greater uncertainty
and high ICERs. This is one way  forward to recognising
other sources of evidence through greater patient, clinician
and public participation (patient experiences, care path-
ways) [43], as well as the value of qualitative evidence
[2,43].
When comparing the criteria across these programmes,
the information requested is similar (Table 1). These crite-
ria are accounted for through NICE’s consultee submissions
or SMC’s PACE statements and ultra-OMP explicit decision-
making framework, and discussed during the appraisal
committees’ deliberations. While NICE has a committee
dedicated to the HST programme, the same Committee
evaluates all drugs at SMC. Additionally, NICE’s patient
and clinician submission templates provide more detailed
guidance about the type of evidence to be provided com-
pared to SMC’s PACE submission template [35,44]. It is not
clear whether this inﬂuences the level of detail provided
during these processes. Our examples also showed thatA programme response to the challenges of deal-
 selected European countries. Health Policy (2017),
these additional criteria may  not be sufﬁcient to accept
poor value for money (e.g. SMC  for elosulfase alfa). One  of
the main issues highlighted by SMC, but not by NICE, are
the extremely high ICERs encountered. This suggests that
 ING Model
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despite accounting for similar criteria (Table 1), differences
may  be seen in their consideration.
While one of the main criticisms of traditional cost-
effectiveness models is the failure to capture multiple
attributes of the value of an OMP, a number of studies
have tried to deﬁne these [societal preferences]. We  have
seen earlier that rarity does not justify a special status, but
other attributes may. One recent study identiﬁed some of
these societal preferences, which included disease severity,
the rule of rescue (priority to the more urgent conditions),
other patient attributes (e.g. age, parent and caregiver
status), and (non) smokers [24]. Paulden and colleagues
(2015) have performed a scoping review of the social value
arguments put forward and against the reimbursement of
orphan drugs [42]. They propose a value framework with
the factors that should be considered in the decision, which
include value-bearing factors (e.g. disease-, treatment-,
population-, and socio-economic-related factors), oppor-
tunity cost-determining factors (e.g. cost of treatment,
budget impact), and other factors (e.g. feasibility of diag-
nosis and of treatment). They also consider the patient,
physician and societal preferences, as well as the rule of
rescue, the equity principle and the rights based approach.
Most of these are captured in the ultra-OMP frameworks,
either through their eligibility criteria (e.g. prevalence),
their process (e.g. accounting for stakeholder input), or
in the criteria considered. The following, however, were
not captured: the identiﬁability of the treatment beneﬁ-
ciaries (tendency to give preference to visible individuals,
e.g. rule of rescue), the treatment’s innovative nature [45],
the feasibility of diagnosing the disease and providing the
treatment, industrial and commercial policy, legal con-
siderations, or certain patient attributes. Similar criteria
were also accounted in the ultra-OMP frameworks to those
deﬁned as the normative universal criteria included in the
EVIDEM framework, which aims “to evaluate interventions
and facilitate their prioritization using a comprehensive set
of decision criteria” based on the criteria rooted in differ-
ent ethical positions” [46]. These examples suggest that the
criteria included in the ultra-OMP frameworks correspond
to those highlighted as relevant for both OMPs and non-
OMPs, despite in some instances, a lack of consensus in the
literature as to whether these should be considered.
Whether the ICER is still relevant for ultra-OMPs is obvi-
ously a key question. For example, since 2002, a distinction
has been made in Belgium between the reimbursement cri-
teria for OMPs and other drugs. Cost-effectiveness is not
mandatory for OMPs. An OMP  is reimbursed if there is
a high medical need, a clinically signiﬁcant effect and an
acceptable budget impact. Interestingly NICE and SMC  do
review budget impact, but it has not been a part of decision-
making. This is an important consideration for ultra-OMPs.
NICE utilises a national risk-sharing scheme to support
implementation via the HST programme. There is currently
no comparable scheme in NHS Scotland. The SMC  remit
excludes affordability.
However, as we see increasingly high prices for orphansPlease cite this article in press as: Nicod E, et al. HT
ing with orphan medicinal products: Process evaluation i
http://dx.doi.org/10.1016/j.healthpol.2017.03.009
and ultra-OMPs, some mechanism is needed to ensure
fairness for all those in the health system including the
opportunity costs these high cost OMPs will bring. While
both NICE and SMC’s programmes recognise the need to PRESS
 xxx (2017) xxx–xxx
go beyond cost/QALY estimates, one important considera-
tion is how these new programmes are being implemented
and whether they ensure accountability for reasonable-
ness and consistency in the way the criteria are accounted
for. Their explicit consideration during the deliberative
process is already one step forward to making sure they
are examined, but more could be done to gain interna-
tional multi-stakeholder agreement on the wider elements
of value and to ensure that deliberative processes docu-
ment how these new elements have contributed to the
decision. New approaches such as multiple criteria deci-
sion analysis (MCDA) not only ensure consideration of
these elements, but also give them an explicit weight
that can be derived through stakeholder participation [47].
MoCA takes account of this. Additionally, other features
encountered with orphan drugs include issues such as of
salami-slicing, drug repurposing or the making of excessive
proﬁts [10]. The current systems fail to account for multiple
indications and whether excessive proﬁts are being made
or to distinguish between products developed de novo and
“repurposed” drugs, with much lower development costs.
These would not be accounted for explicitly when assessing
their value, but should be regarded by the decision-makers
during the deliberative process.
While such innovative approaches and greater stake-
holder participation and inclusion of other forms of
evidence may  help go beyond the ICER, uncertainty will still
be present. This could be managed by additional evidence
generation after HTA approval to allow reassessment, e.g.
via MAA/PAS, registries and real world data to collect natu-
ral history and longer term outcomes [2]. This was seen in
our illustrative examples, and allowed to better deal with
uncertainty or high costs, sharing the associated risks with
the manufacturer, or accepting uncertainty until additional
evidence is available.
Both the HST and SMC  programmes for OMP  and ultra-
OMPs are at early stages and currently under review [48].
This is also the case for MoCA. There are still a number
of open questions about their application, and the ongo-
ing issue of having to deal with extremely high ICERs
and uncertain evidence. The question therefore arises as
to whether these processes are still sufﬁcient or whether
there is a need to look at new ways to assessing value. The
potential added value of the MoCA project is of key impor-
tance within this context, in fostering a multi-stakeholder
dialogue in view of reaching greater consensus when dis-
cussing the determinants of a product’s value at earlier
stages and throughout the drug development process. This
early and continuous dialogue will contribute to improv-
ing the efﬁciency (and effectiveness) of drug development
[49]. The importance of this approach is highlighted by
the Adaptive Pathways initiative of the EMA, which does
not speciﬁcally address OMPs, but does include them [50].
In a context where a number of new value frameworks
for prescription drugs and OMPs are being developed
[51,52], MoCA has the potential to bring together these
new models and gain more experience in order to ﬁndA programme response to the challenges of deal-
n selected European countries. Health Policy (2017),
out how best to integrate these processes and reduce
the complexities encountered from these multiple sys-
tems.
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. Conclusions
Two HTA bodies in the UK have recognized that OMPs
r ultra-OMPs operate in a context of greater uncertainty
ue to clinical, regulatory and economic challenges and
esponded to this by creating new bespoke programmes
or these products. These encourage alternative economic
odels to the standard cost-utility approaches and man-
ged entry agreements in the form of patient access
chemes and managed access agreements to collect real
orld data. In addition, the HTA appraisal decision-making
riteria is extended beyond the cost/QALY, to consider
 more holistic framework that considers disease and
reatment experiences and uncertainty from a range of
takeholders. The question arises as to whether these new
rogrammes and decision-making frameworks will be suc-
essful in capturing value and dealing with uncertainty.
hat is needed are trials that answer the question that
ayers and HTA bodies will pose. Payers have recognized
his issue and MoCA is seeking to foster multi-national
nd multi-stakeholder dialogue and reach consensus about
he determinants of a product’s value throughout the drug
evelopment process. Although discussions around spe-
iﬁc products are conﬁdential, the process needs to be
valuated and the challenges and issues faced in all these
rogrammes need to be shared widely.
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